Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01098487 · ClinicalTrials.gov registry record · Phase 4
A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 167
- Enrollment target
NCT01098487 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 167 participants.
The verdict
NCT01098487, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 167 participants
- Enrollment target
Study Summary
A open-label, multi-center 2-year safety study to ascertain the baseline levels of bone marrow fibers in previously treated adults with chronic immune (idiopathic) thrombocytopenic purpura (ITP) and to evaluate the long-term effect of eltrombopag on bone marrow fibers. The study will also describe the long-term safety and tolerability of oral eltrombopag treatment in subjects with chronic ITP.
Interventions
- DRUG Eltrombopag olamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2010-05 |
| Est. Completion | 2014-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01098487
The ClinicalTrials.gov registry entry for NCT01098487 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 167 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Eltrombopag olamine is the first listed.
NCT01098487 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01098487 about?
NCT01098487 is a clinical study titled "A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)". A open-label, multi-center 2-year safety study to ascertain the baseline levels of bone marrow fibers in previously treated adults with chronic immune (idiopathic) thrombocytopenic purpura (ITP) and to evaluate the long-term effect of eltrombopag on bone marrow fibers. The study will also describe t...
What is the current status of trial NCT01098487?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 167 participants. The study started on 2010-05. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01098487?
The interventions under investigation include: Eltrombopag olamine (DRUG).
Who is sponsoring clinical trial NCT01098487?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.